MarketPeel
Insider Trading Intelligence
Pricing
…
JB

John P. Butler

AKBA
CEO AND PRESIDENT · AKEBIA THERAPEUTICS, INC. · CIK 0001591467
FILING MIX · LIFETIME49%/51%
BUYS
20
SELLS
21
TOTAL VALUE
$1.87M
COMPANIES
1
ACTIVE SINCE
Dec 2018
HOLDINGS NOW
3,367,064
AVG SELL PX
$1.66
TRADE KIND
SHOWING 41 / 41
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
22 backtested trades · 8 horizons · 18 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by John P. Butler, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d22+40.91%+6.81%-0.51%+7.31%+8.91%—
14d22+68.18%-4.49%-0.46%-4.03%-7.95%—
30d22+72.73%-19.28%+1.68%-20.96%-8.16%—
60d22+68.18%-15.89%-0.82%-15.07%-10.27%—
90d22+31.82%-10.69%+2.37%-12.69%-2.08%—
180d22(5 pending)+58.82%+0.98%+7.19%-6.21%-16.81%—
1y22(5 pending)+58.82%-6.33%+14.23%-20.56%-47.95%—
2y22(8 pending)+71.43%+2.58%+31.17%-28.59%-48.42%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AKBA · 3,367,064 shares · as of Mar 4, 2026
0865,9621,731,9252,597,8873,463,84920192020202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2018
2019
2019
2019
2019
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 20 buys / 21 sellsCOVERAGE · 30 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASE
CEO and President
69,270$1.25$86.6K3,367,064Mar 4, 2026Mar 5, 2026 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
114,891$1.39$159.7K3,206,233Feb 2, 2026Feb 4, 2026 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
83,689$1.39$116.3K3,297,794Feb 2, 2026Feb 4, 2026 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
175,250$1.41$247.1K3,381,483Feb 2, 2026Feb 4, 2026 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
96,065$1.39$133.5K3,321,124Feb 2, 2026Feb 4, 2026 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
46,660$1.39$64.9K3,417,189Feb 2, 2026Feb 4, 2026 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
743,000——3,463,849Jan 30, 2026Feb 3, 2026 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,115,000——1,115,000Jan 30, 2026Feb 3, 2026 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
46,409$1.83$84.9K2,557,921Mar 3, 2025Mar 4, 2025 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
46,268$2.10$97.2K2,702,312Feb 3, 2025Feb 4, 2025 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
97,982$2.10$205.8K2,604,330Feb 3, 2025Feb 4, 2025 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
701,000——2,748,580Jan 31, 2025Feb 4, 2025 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
350,500——350,500Jan 31, 2025Feb 4, 2025 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,051,400——1,051,400Jan 31, 2025Feb 4, 2025 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
46,570$1.58$73.6K2,044,580Feb 29, 2024Mar 1, 2024 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
37,733$1.52$57.4K2,091,150Feb 27, 2024Feb 29, 2024 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
46,489$1.68$78.1K2,128,883Feb 1, 2024Feb 2, 2024 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
603,500——2,175,372Jan 31, 2024Feb 2, 2024 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
905,200——905,200Jan 31, 2024Feb 2, 2024 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
47,239$0.88$41.5K1,575,242Mar 1, 2023Mar 3, 2023 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
38,259$0.88$33.6K1,622,481Mar 1, 2023Mar 3, 2023 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
6,370$0.88$5.6K1,568,872Mar 1, 2023Mar 3, 2023 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
38,632$0.81$31.4K1,660,740Feb 27, 2023Mar 1, 2023 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
293,125——1,699,372Jan 31, 2023Feb 2, 2023 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
875,000——875,000Jan 31, 2023Feb 2, 2023 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
635,313——635,313Jan 31, 2023Feb 2, 2023 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
25,031$2.17$54.3K1,407,378Mar 1, 2022Mar 2, 2022 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
4,131$2.17$9.0K1,403,247Mar 1, 2022Mar 2, 2022 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
24,811$2.17$53.9K1,432,409Mar 1, 2022Mar 2, 2022 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
25,053$2.15$54.0K1,164,095Feb 28, 2022Mar 2, 2022 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
739,700——739,700Feb 28, 2022Mar 2, 2022 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
293,125——1,457,220Feb 28, 2022Mar 2, 2022 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
4,109$3.40$14.0K1,152,153Apr 1, 2021Apr 1, 2021 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
39,520——1,156,262Mar 16, 2021Mar 18, 2021 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
25,316$3.40$86.0K1,141,416Mar 1, 2021Mar 2, 2021 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
SALE
CEO and President
24,674$3.40$83.8K1,116,742Mar 1, 2021Mar 2, 2021 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
403,600——403,600Feb 26, 2021Mar 2, 2021 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
237,400——1,166,732Feb 26, 2021Mar 2, 2021 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
237,400——1,026,632Feb 28, 2020Mar 2, 2020 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
403,600——403,600Feb 28, 2020Mar 2, 2020 ↗View →
AKBA
AKEBIA THERAPEUTICS, INC.
PURCHASE
CEO and President
1,248——375,865Dec 12, 2018Feb 18, 2022 ↗View →
Other insiders · AKBA
Loading peer insiders…
About this filer
CIK 0001591467
ROLE
CEO and President
PRIMARY
AKBA
COMPANIES
1
ACTIVE SINCE
Dec 2018
MARKETPEEL · /INSIDER/0001591467DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback